Sleep-wake effects of meta-chlorophenyl piperazine and mianserin in the behaviorally depressed rat

European Journal of Pharmacology

Volumn 455, Issue 1, 2002, Pages 35-41

  Mavanji, Vijayakumar ^a,b   Meti, Basavalingappa ^b   Datta, Subimal ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

5 HT (5 hydroxytryptamine, serotonin); Animal model; Depression; Endogenous; mCPP; Mianserin; REM (rapid eye movement) sleep

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; CLOMIPRAMINE; MIANSERIN; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REM SLEEP; SLEEP STAGE; SLEEP WAKING CYCLE;

ANIMALS; BEHAVIOR, ANIMAL; DEPRESSION; INJECTIONS, INTRAVENTRICULAR; MALE; MIANSERIN; PIPERAZINES; RATS; RATS, WISTAR; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SLEEP, REM;

EID: 0037159607     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02553-0     Document Type: Article

References (62)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 4th ed. 1994;APA, Washington, DC.
2. Bauman M.H., Rutter J.J., Auerbach S.B. Intravenous administration of serotonin agonist m-chlorophenylpiperazine (mCPP) increases extracellular serotonin in the diencephalon of awake rats. Neuropharmacology. 32:1993;1381-1386.
3. Blair P., Demontigny C., Azzaro A.J. Modification of serotonergic and noradrenergic neurotransmission by repeated administration of monoamine oxidase inhibitors: electrophysiological studies in the rat central nervous system. J. Pharmacol. Exp. Ther. 237:1986;987-994.
4. Boutrel B., France B., Hen R., Hamon M., Adrien J. Key role of 5-HT1B receptors in the regulation of paradoxical sleep as evidenced in 5-HT1B knockout mice. J. Neurosci. 19:1999;3204-3212.
5. Bunney W.E., Davis J.M. Norepinephrine in depressive reactions. Arch. Gen. Psychiatry. 13:1965;483-491.
6. Coppen A. Depressed states and indolealkylamines. Coppen A. Advances in Pharmacology. 1968;283-291 Academic Press, New York, NY.
7. Datta S. Neuronal activity in the peribrachial area: relationship to behavioral state control. Neurosci. Biobehav. Rev. 19:1995;67-84.
8. Datta S. Cellular basis of pontine ponto-geniculo-occipital wave generation and modulation. Cell. Mol. Neurobiol. 17:1997;341-365.
9. Datta S., Hobson J.A. The rat as an experimental model for sleep neurophysiology. Behav. Neurosci. 114(6):2000;1239-1244.
10. Datta S., Kumar V.M., Chinna G.S., Singh B. Effect of application of serotonin in medial preoptic area on body temperature and sleep-wakefulness. Indian J. Exp. Biol. 25:1987;681-685.
11. Datta S., Calvo J.M., Quattrochi J.J., Hobson J.A. Cholinergic micro-stimulation of the peribrachial nucleus in the cat: immediate and prolonged increase in ponto-geniculo-occipital waves. Arch. Ital. Biol. 130:1992;263-284.
12. Datta S., Patterson E.H., Vincitore M., Tonkiss J., Morgane P.J., Galler J.R. Prenatal protein malnourished rats show changes in sleep-wake behavior as adults. J. Sleep Res. 9:2000;71-79.
13. Datta S., Spoley E.E., Patterson E.H. Microinjection of glutamate in to the pedunculopontine tegmentum induces REM sleep and wakefulness in rat. Am. J. Physiol., Regul. Integr. Comp. Physiol. 280:2001;R752-R759.
14. Delgado P.L., Charney D.S., Price L.H. Serotonin function and the mechanism of antidepressant action: reversal of antidepressant induced remission by rapid depletion of plasma tryptophan. Arch. Gen. Psychiatry. 47:1990;411-418.
15. Dugovic C., Van Den Broeck W.A.E. Sleep-wakefulness alterations produced by the putative serotonin 5-HT1C agonist m-chlorophenylpiperazine in the rat. Sleep Res. 20A:1991;129.
16. Fuller R.W., Snoddy H.D., Mason N.R., Owen J.E. Disposition and pharmacological effects of m-chlorophenylpiperazine in rats. Neuropharmacology. 20:1981;155-162.
17. Gillin J.C., Sitaram N., Mendelson W.B. Acetylcholine, sleep and depression. Hum. Neurobiol. 1:1982;211-219.
18. Gillin J.C., Salin-Pascual R., Velazquez-Moctezuma J., Shiromani P.J., Zoltoski R. Cholinergic receptor subtypes and REM sleep in animals and normal controls. Prog. Brain Res. 98:1993;379-387.
19. Gleason S.D., Lucaites V.L., Shannon H.E., Nelson D.L., Leander J.D. mCPP hypolocomotion is selectively antagonized by compounds with high affinity for 5-HT(2C) receptors but not 5-HT(2A) or 5-HT(2B) receptors. Behav. Pharmacol. 12:2001;613-620.
20. Hans-Peter L., Eric R., Bradley J.S., John K.R., Mark R.H., Gillin J.C. Sleep and sleep electroencephalogram in depressed patients treated with phenelzine. Arch. Gen. Psychiatry. 58:2001;268-276.
21. Harkin A., Kelly J.P., McNamara M., Connor T.J., Dredge K., Redmond A., Leonard B.E. Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression. Eur. J. Pharmacol. 364:1999;123-132.
22. Hartley P., Neill D., Hagler M., Kors D., Vogel G. Procedure- and age-dependent hyperactivity in a new animal model of endogenous depression. Neurosci. Biobehav. Rev. 14:1990;69-72.
23. Horner R.L., Sanford L.D., Annis D., Pack A.I., Morrison A.R. Serotonin at the laterodorsal tegmental nucleus suppresses rapid eye movement sleep in freely behaving rats. J. Neurosci. 17:1997;7541-7552.
24. Jouvet M. The role of monoamines and acetylcholine containing neurons in the regulation of sleep-waking cycle. Ergeb. Physiol. Biol. Chem. Exp. Pharmakol. 64:1972;166-307.
25. Kinney G.G., Vogel G.W., Pingfu F. Decreased dorsal raphe nucleus neuronal activity in adult chloral hydrate anesthetized rats following neonatal clomipramine treatment: implications for endogenous depression. Brain Res. 756:1997;68-75.
26. Lawlor B.A., Newhouse P.A., Balkin T.J. A preliminary study of the effects of nighttime administration of the serotonin agonist, mCPP, on sleep architecture and behavior in healthy volunteers. Biol. Psychiatry. 29:1991;281-286.
27. Mavanji V.K., Meti B.L. Alteration in the levels of monoamines in discrete brain regions of clomipramine-induced animal model of endogenous depression. Neurochem. Res. 24:1999;345-349.
28. McCarley R.M. REM sleep and depression: common neurobiological control mechanisms. Am. J. Psychiatry. 139:1982;565-570.
29. McCracken J.T., Poland R.E., Lutchmansingh P., Edwards C. Sleep electroencephalographic abnormalities in adolescent depressives: effects of scopolamine. Biol. Psychiatry. 42:1997;577-584.
30. Mendlewicz J., Dunbar J.C., Hoffman G. Changes in sleep EEG architecture during the treatment of depressed patients with mianserin. Acta Psychiatr. Scand. 72:1985;26-29.
31. Monti J.M., Monti D. Functional role of serotonin 5-HT1 and 5-HT2 receptor in the regulation of REM sleep. Mallick B.N., Inoue S. Rapid Eye Movement Sleep. 1999;142-152 Narosa Publishing House, New Delhi.
32. Neil D., Vogel G., Hagle M., Kors D., Hennessey A. Diminished sexual activity in a new animal model of endogenous depression. Neurosci. Biobehav. Rev. 14:1990;73-76.
33. Nelson J.C. Synergistic effects of seronergic and noradrenergic antidepressants in combination. Briley M., Montogmery S. Antidepressant Therapy at the Dawn of the Third Millenium. 1997;297-305 Martin Dunitz, UK.
34. Pare C.M.B., Yeung D.P.H., Price K., Stancey R.S. 5-Hydroxytryptamine, noradrenaline and dopamine in brain stem, hypothalamus and caudate nucleus of controls and patients committing suicide by coal gas poisoning. Lancet. 2:1969;133-135.
35. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic Press, San Diego.
36. Pinder R.M. Designing a new generation of antidepressant drugs. Acta Psychiatr. Scand. 96:1997;7-13.
37. Pinder R.M., Fink M. Mianserin. Mod. Probl. Pharmacopsychiatry. 18:1982;70-101.
38. Portas C.M., McCarley R.W. Behavioral state related changes of extracellular serotonin concentration in the dorsal raphe nucleus: a microdialysis study in the freely moving cat. Brain Res. 648:1994;306-312.
39. Portas C.M., Bjorvatn B., Fagerland S., Gronli J., Mundal V., Sorensen E., Ursin R. On-line detection of extracellular levels of serotonin in dorsal raphe nucleus and frontal cortex over the sleep/wake cycle in the freely moving rat. Neuroscience. 83:1998;807-814.
40. Python A., Charnay Y., Mikolajewski R., Merica H., De Saint Hilare Z. Effects of nisoxetine, a selective noradrenaline transporter blocker, on sleep in rats. Pharmacol. Biochem. Behav. 58:1997;369-372.
41. Quattrochi J.J., Mamelak A., Binder D.K., Williams J., Rittenhouse C., Hobson J.A. Dynamic suppression of REM sleep by parenteral administration of the central serotonin-1 agonist eltropazine. Sleep. 15:1992;125-132.
42. Reynolds C.F., Kupfer D.J. Sleep research in affective illness: state of the art review. Sleep. 10:1987;199-215.
43. Richard A.G. Central serotonin receptors as targets for drug research. J. Med. Chem. 30:1987;1-12.
44. Sanford L.D., Ross R.J., Seggos A.E., Morrison A.J., Ball W.A., Mann G.L. Central administration of two 5-HT receptor agonists: effects on REM sleep initiation and PGO waves. Pharmacol. Biochem. Behav. 49:1994;93-100.
45. Sanford L.D., Tejani-Butt S.M., Ross R.J., Morrison A.J. Amygdaloid control of alerting and behavioral arousal in rats: involvement of serotonergic mechanisms. Arch. Ital. Biol. 134:1995;81-99.
46. Sharpley A.L., Cowen P.J. Effects of pharmacological treatments on the sleep of depressed patients. Biol. Psychiatry. 37:1995;85-98.
47. Shaw D.W., Camps F.E., Eccleston E.G. 5-Hydroxy tryptamine in the hind brain of depressive suicides. Br. J. Psychiatry. 113:1967;1407-1411.
48. Shopsin B., Gershan S., Goldstein M. Use of synthesis inhibitors in defining a role for a biogenic amines during imipramine treatment in depressed patients. Psychopharmacol. Commun. 2:1975;239-249.
49. Shopsin B., Friedman E., Gershan S. P-chlorophenylalanine reversal of tranylcypromine effect in depressed patients. Arch. Gen. Psychiatry. 33:1976;811-819.
50. Sitaram N., Nurnberger J., Gershon E.S., Gillin J.C. Cholinergic regulation of mood and REM sleep: a potential model and marker for vulnerability to depression. Am. J. Psychiatry. 139:1982;571-576.
51. Stickgold R., Williams J., Datta S., Quattrochi J., Hobson J.A. Suppression of eltoprazine-induced REM sleep rebound by scopolamine. Neuropharmacology. 32:1993;447-453.
52. Thase M., Reynolds C., Frank E., Jennings J., Nofzinger E., Fasiczka A., Garamoni G., Kupfer D. Polysomnographic studies of unmedicated depressed men before and after cognitive therapy. Am. J. Psychiatry. 151:2001;1615-1622.
53. Tormey W.P., Buckley M.P., Okelly D.A., Conboy J., Pinder R.M., Darragh A. Sleep endocrine profile of the antidepressant mianserin. Curr. Med. Res. Opin. 6:1980;456-460.
54. Victor J.N., Joop H.W., Vandelft A.M.L. Comparative pharmacology of mianserin, its main metabolites and 6-azamianserin. Naunyn-Schmiedeberg's Arch. Pharmacol. 319:1982;48-55.
55. Vizi E.S., Harsing L.G., Zsilla G. Evidence of the modulatory role of serotonin in acetylcholine release from striatal interneurons. Brain Res. 212:1981;89-99.
56. Vogel G.W., Vogel F.A. A new animal model of human endogenous depression. Sleep Res. 11:1982;222a.
57. Vogel G.W., Thurmond A., Gibbons P., Sloan K., Boyd M., Walker M. REM sleep reduction effects on depression syndromes. Arch. Gen. Psychiatry. 32:1975;765-777.
58. Vogel G.W., Hartley P., Neil D., Hagler M., Kors D. Animal depression model by neonatal clomipramine: reduction of shock induced aggression. Pharmacol. Biochem. Behav. 31:1988;103-106.
59. Vogel G.W., Neil D., Hagler M., Kors D. A new animal model of endogenous depression: a summary of present findings. Neurosci. Biobehav. Rev. 14:1990;85-91.
60. Yates M., Leake A., Candy J.M., Fairbairn A.F., McKeith I.G., Ferrier I.N. 5-HT2 receptor changes in major depression. Biol. Psychiatry. 27:1990;477-488.
61. Yoshiaki K., Anne E.S.W., Chris J.W., Cowen P.J., Sharpley A.L. Meta-chlorophenylpiperazine decreases slow-wave sleep in humans. Biol. Psychiatry. 33:1993;49-51.
62. Young S.N., Smith S.E., Pihl R., Ervin F.R. Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology. 87:1985;173-177.